ホーム › 急性骨髄性白血病 › ノースカロライナ › Winston-Salem
Winston-Salem、NCにおける急性骨髄性白血病の臨床試験
Winston-Salemとその周辺地域（約30マイル以内）の拠点で、急性骨髄性白血病に関する18件の研究が参加者を募集しています。研究を開いて、参加資格と連絡方法を確認してください。
公式研究テキスト（英語）
ここで研究参加者を募集していますか？ このページの上部に表示できます — 30日間 $99 →
MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
被験者募集中第2相
- Novant Health Forsyth Medical Center, Winston-Salem
- Wake Forest University Health Sciences, Winston-Salem
Testing the Anti-cancer Drug, Cirtuvivint, and Its Combination With ASTX727 to Improve Outcomes in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndromes
被験者募集中第1相
- Wake Forest University Health Sciences, Winston-Salem
Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)
被験者募集中第2相
- Novant Health Forsyth Medical Center, Winston-Salem
- Wake Forest University Health Sciences, Winston-Salem
A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)
被験者募集中第3相
- Novant Health Winston Salem, Winston-Salem
- Atrium Health Wake Forest Baptist Comprehensive Cancer Center, Winston-Salem
Comparing New Treatments for People With Newly Diagnosed Acute Myeloid Leukemia That Has an IDH2 Gene Change (A MyeloMATCH Treatment Trial)
被験者募集中第2相
- Wake Forest University Health Sciences, Winston-Salem
Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)
被験者募集中第2相
- Wake Forest University Health Sciences, Winston-Salem
Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)
被験者募集中第2相
- Wake Forest University Health Sciences, Winston-Salem
A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations
被験者募集中第3相
- Wake Forest University Health Sciences, Winston-Salem
Olutasidenib in Relapsed IDH1 Mutated AML Patients Who Have Previously Received Venetoclax
被験者募集中第2相
- Atrium Health Wake Forest Baptist Medical Center, Winston-Salem
The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
被験者募集中第1/2相
- Wake Forest University Health Sciences, Winston-Salem
A Phase 1b Study of Menin Inhibitor SNDX- 5613 in Combination With Daunorubicin and Cytarabine in Newly Diagnosed Patients With Acute Myeloid Leukemia and NPM1 Mutated/FLT3 Wildtype or MLL/KMT2A Rearranged or NUP98 Alterations Disease
被験者募集中第1相
- Wake Forest University Health Sciences, Winston-Salem
Toxicity Genetic Determinants and Response to Azacitidine and Venetoclax in AML
被験者募集中観察研究
- Wake Forest Baptist Comprehensive Cancer Center, Winston-Salem
ONC-LEUK-2406: The Impact of Systematic Financial Navigation in Acute Myeloid Leukemia
被験者募集中
- Atrium Health Wake Forest Baptist Comprehensive Cancer Center, Winston-Salem
Tagraxofusp and Azacitidine With Venetoclax in Newly Diagnosed Secondary AML After Hypomethylating Agents
被験者募集中第2相
- Atrium Health Wake Forest Baptist Comprehensive Cancer Center, Winston-Salem
A Decisional Intervention for Older Adults With Acute Myeloid Leukemia and Their Caregivers
被験者募集中
- Atrium Health Wake Forest Baptist Comprehensive Cancer Center, Section of Hematology/Oncology, Winston-Salem
The Prospective Collection, Storage and Reporting of Data on Patients Undergoing Hematopoietic Stem Cell Transplantation Utilizing a Standard Preparative Regimen
被験者募集中観察研究
- Wake Forest Baptist Health, Winston-Salem
A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)
被験者募集中第1/2相
- Atrium Wake Forest Baptist Medical Center, Winston-Salem
Clinical Study of ARD103 CAR-T Therapy for Patients With R/R AML or MDS
被験者募集中第1/2相
- Novant Health Cancer Institute, Winston-Salem
他の都市における急性骨髄性白血病の試験
- Houston, TX85件の研究
- New York City, NY51件の研究
- Boston, MA44件の研究
- Seattle, WA41件の研究
- Baldwin Park, CA40件の研究
- Columbus, OH35件の研究
- Philadelphia, PA34件の研究
- Durham, NC33件の研究
- Atlanta, GA31件の研究
- Tampa, FL29件の研究
- Chicago, IL26件の研究
- Portland, OR25件の研究
Winston-Salemにおける他の研究
- がん（全種類）19件の研究
- 多発性骨髄腫14件の研究
- 乳がん14件の研究
- 心血管疾患14件の研究
- 非小細胞肺癌12件の研究
- COPD10件の研究
- 卵巣がん10件の研究
- 2型糖尿病9件の研究
- 骨髄異形成症候群9件の研究
- 膠芽腫8件の研究
- 慢性リンパ性白血病8件の研究
- 肺がん8件の研究
ClinicalTrials.govより、2026/10/06時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。